|
186 Products |
| 186 Products |
|
1696 Diseases |  |
94663 News |  |
| «12...3839404142434445464748...10631064» |
- Ninlaro (ixazomib) / Takeda
IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01 (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2502;
This dataconfirms the importance of proteasome inhibitors in HR RRMM. This phase 2 study needs confirmation in alarger cohort.
- Elrexfio (elranatamab-bcmm) / Pfizer, Actemra IV (tocilizumab) / Roche, JW Pharma, Tecvayli (teclistamab-cqyv) / Genmab, J&J
EFFECTIVENESS AND SAFETY OF BISPECIFIC ANTIBODIES TARGETING BCMA AND CD3 IN PATIENTS WITH CENTRAL NERVOUS SYSTEM MULTIPLE MYELOMA (CNS-MM): IFM 2023-06, A RETROSPECTIVE COHORT STUDY. (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2501;
The incidence of CRS, ICANS, infections appears to becomparable with those seen in clinical trials. More data and follow up are needed to describe the clinicalbenefit and medium term outcome.
- Darzalex Faspro (daratumumab/hyaluronidase) / J&J
OUTCOMES OF PATIENTS WITH EXTRAMEDULLARY DISEASE AND RELAPSED OR REFRACTORY MULTIPLE MYELOMA FROM HISTORICAL CLINICAL TRIALS (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2500;
Patients with RRMM and EMD have a significantly lower ORR than those without EMD, even in studiescomparing standard and novel, highly effective regimens. Future clinical trials with innovative therapies areessential to overcome the poor prognosis in the high-risk EMD patient population to address this unmetmedical need.
- lisaftoclax (APG-2575) / Ascentage Pharma
LISAFTOCLAX (APG-2575) COMBINED WITH NOVEL THERAPEUTIC REGIMENS IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) MULTIPLE MYELOMA (MM) OR IMMUNOGLOBULIN LIGHT-CHAIN (AL) AMYLOIDOSIS (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2499;
P1/2
Future clinical trials with innovative therapies areessential to overcome the poor prognosis in the high-risk EMD patient population to address this unmetmedical need. Aims: The aim of this multicenter study was to evaluate the safety and efficacy of lisaftoclax combined withpomalidomide and dexamethasone (Arms A and C) or daratumumab, lenalidomide, and dexamethasone (ArmB) in pts with R/R MM (Arm A and B) or R/R AL amyloidosis (Arm C)...Pomalidomide, daratumumab, and lenalidomide were administered per label use...Lisaftoclax plus novel therapeutic regimens was well tolerated and demonstrated preliminary antitumor activityin both pts with R/R MM or AL amyloidosis.
- Ninlaro (ixazomib) / Takeda, iberdomide (CC-220) / BMS
ALL-ORAL TRIPLET IBERDOMIDE IXAZOMIB AND DEXAMETHASONE IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA AT FIRST RELAPSE: RESULTS OF THE IFM PHASE 2 STUDY I2D (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2498;
P2
Background: The triplet combination daratumumab, lenalidomide and dexamethasone (DRd) and bortezomib, lenalidomideand dexamethasone (VRd) are to date the standard of care for patients with transplant ineligible (TI) newlydiagnosed multiple myeloma (MM)...Iberdomide is a novel oralcereblon E3 ligase modulator (CELMoD) that demonstrated promising activity in MM patients refractory tolenalidomide/pomalidomide... The oral triplet** iberdomide, ixazomib and dexamethasone demonstrated a favorable efficacy / safety profilein elderly MM patients at first relapse, including in patients with lenalidomide and daratumumab refractorydisease.
- Venclexta (venetoclax) / Roche, AbbVie
EFFICACY OF VENETOCLAX-DEXAMETHASONE V POMALIDOMIDE-DEXAMETHASONE IN PATIENTS WITH T(11; 14)-POSITIVE RELAPSED/REFRACTORY MULTIPLE MYELOMA [T(11; 14)+ RRMM]:PHASE 3 CANOVA BIOMARKER SUBGROUP ANALYSIS (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2494;
P3
Clinical benefit was consistent across BCL2 subgroups (BCL2high or BCL2low) with VenDex but notPomDex. Pts with amp(1q) fared poorly irrespective of treatment arm.
- ABBV-383 IV / AbbVie
CORRELATIVE BIOMARKER ANALYSES FOR OPTIMAL THERAPEUTIC DOSE DETERMINATION OF ABBV-383, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2491;
P1/2
Pts with amp(1q) fared poorly irrespective of treatment arm. Peripheral blood and serum samples from patients with relapsed/refractory multiple myeloma (RRMM)enrolled in the phase 1 open-label, dose-expansion study (NCT03933735) who received ABBV-383 at 20, 40, or60 mg Q3W or 60 mg Q4W were collected at baseline (post-dexamethasone, pre
- Blenrep (belantamab mafodotin-blmf) / GSK
A PATIENT-REPORTED QUESTIONNAIRE MAY ELIMINATE THE NEED FOR AN OPHTHALMIC EXAM BEFORE BELANTAMAB MAFODOTIN DOSING IN NEWLY DIAGNOSED TRANSPLANT-INELIGIBLE PATIENTS WITH MULTIPLE MYELOMA (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2490;
P1/2
Furthermore, a highconcordance rate between VRA and the ophthalmologist's assessment was observed in ?Gr3 OAEs. Furtheranalyses will determine if VRA can effectively replace an ophthalmic exam to determine belamaf dosing.
- Darzalex (daratumumab) / J&J, Ninlaro (ixazomib) / Takeda
THE NEED FOR REDUCING RELAPSE RISK IN CYTOGENETICALLY HIGH-RISK MULTIPLE MYELOMA: IMPROVING OR OPTIMIZING MAINTENANCE MANAGEMENT (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2488;
Currently, maintenance therapy of NDMM is in the stagewhere lenalidomide (Len) stands as the standard of care with available maintenance regimens also involvingbortezomib (Btz), daratumumab (Dara), ixazomib (Ixa), carfilzomib (Car), prednisone (Pdn) anddexamethasone (Dex)...The addition of dexamethasone (Dex) might increase the occurrence of relapse in high-risk NDMM patientscompared to Dex-free maintenance regimens, most notably as LenDex vs Len (RR=1... Collectively, this study presented the current landscape of the maintenance of high-risk NDMM patients andhighlighted the urgency of improved maintenance therapies available.
- lenalidomide / Generic mfg.
ANTI-CD38 ANTIBODY RETREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PREVIOUSLY TREATED WITH LENALIDOMIDE AND AN ANTI-CD38 ANTIBODY: REAL-WORLD DATA USING THE US FLATIRON DATABASE (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2487;
This retrospective real-world analysis demonstrated that aCD38 retreatment could be a viable treatment optionin pts with RRMM previously treated with LEN and an aCD38. Future prospective studies are needed to confirmthis finding.
- Ninlaro (ixazomib) / Takeda
IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXAPD) PAN-ORAL REGIMEN IN THE TREATMENT OF REFRACTORY AND RELAPSED MULTIPLE MYELOMA (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2483;
P4
The pan-oral IxaPD regimen showed anticipated effect and good tolerance for RRMM patients. More patientsare being enrolled and update data will be reported.
- Xpovio (selinexor) / Karyopharm
OUTCOMES WITH SELINEXOR, BORTEZOMIB AND DEXAMETHASONE (SVD) IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM): REGIONAL SUBGROUP ANALYSIS OF THE PHASE 3 BOSTON TRIAL (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2475;
P3
Some of thesedifferences may have contributed to the favorable efficacy reported with SVd for pts in R1-3. Undescribeddifferences in clinical care and patient education may also have contributed to outcomes.
- Sarclisa (isatuximab-irfc) / Sanofi
CLINICAL EFFICACY OF ISATUXIMAB PLUS CARFILZOMIB -DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: A REAL-LIFE MULTI-CENTER RETROSPECTIVE EXPERIENCE (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2474;
P3
However, prior exposure to anti-CD38 monoclonal antibodies could reduce clinicalefficacy of the combination, thus its use in this group of patients should be carefully considered, especiallybecause of the increased risk of cardiotoxicity and pneumonia complications. .
- bortezomib / Generic mfg., dexamethasone / Generic mfg., lenalidomide / Generic mfg.
WHAT CAN WE TELL OUR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WHO PRESENT WITH SEVERE RENAL INSUFFICIENCY REQUIRING DIALYSIS ABOUT RENAL RECOVERY? A CANADIAN SINGLE-CENTRE ANALYSIS (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2473;
All patients received novel agent-based induction regimens: bortezomib-based in 68patients, (usually CyBorD) and lenalidomide-dexamethasone (RD) in 2 patients; 51 (73%) patients underwenthigh-dose therapy and autologous stem cell transplant (ASCT). In NDMM patients with severe RI, early institution of anti-myeloma therapy with bortezomib-based induction
- Empliciti (elotuzumab) / AbbVie, BMS, Darzalex (daratumumab) / J&J
TREATMENT GOALS AND DECISION-MAKING CRITERIA FOR SECOND- AND THIRD-LINE THERAPY FOR MULTIPLE MYELOMA IN GERMANY (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2470;
For this rather young cohort of pts with RRMM, with a substantial representation of high-risk pts, experiencedMM specialists selected a variety of 2L and 3L regimens with the most frequent primary tx goals to induce thedeepest possible response and to prolong PFS and OS. Good efficacy was considered to be the primary reasonfor prescribing, followed by pt characteristics and other mode of action.
- Ninlaro (ixazomib) / Takeda
EFFICACY AND SAFETY OF IXAZOMIB-BASED SALVAGE THERAPIES IN MULTIPLE MYELOMA PATIENTS WITH A PRIOR HISTORY OF BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2468;
Novel insights into thepathogenesis of PI-induced PN allow for PKNOX1 biomarker-driven approaches to identify patients who wouldpotentially benefit from oral PI-based therapies. Figure 1.
- Sarclisa (isatuximab-irfc) / Sanofi
A PHASE 2 STUDY OF ISATUXIMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RRMM PATIENTS WITH 1 PRIOR LINE OF THERAPY (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2464;
P2
Althoughdata is not yet mature, IsaPoxDex has exhibited promising effectiveness and rapid responses in RRMM pts whohad received one prior line of treatment. Longer follow-up is necessary to better characterize the depth ofefficacy of the combination in this patient population.
- Darzalex (daratumumab) / J&J
REAL-WORLD TREATMENT PATTERNS, EFFICACY, AND SAFETY OF DARATUMUMAB-BASED REGIMENS IN CHINESE PATIENTS WITH MULTIPLE MYELOMA: AN UPDATED ANALYSIS OF THE MMY4032 STUDY (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2463;
Longer follow-up is necessary to better characterize the depth ofefficacy of the combination in this patient population. 5% had priorproteasome inhibitor (PI) use (bortezomib in 80...DARA-based regimens included DARA monotherapy (n=24) and DARA combinedwith dexamethasone (dexa) only (n=20), PI
- Venclexta (venetoclax) / Roche, AbbVie
PATIENT-REPORTED OUTCOMES FROM THE RANDOMIZED PHASE 3 CANOVA STUDY OF VENETOCLAX-DEXAMETHASONE VS POMALIDOMIDE-DEXAMETHASONE IN PATIENTS WITH T(11; 14)-POSITIVE RELAPSED/REFRACTORY MULTIPLE MYELOMA (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2460;
P3
In CANOVA, pts treated with VenDex had delayed median TTDDS and TTDPF compared with those treated withPomDex. These data support a benefit in these PRO measures with VenDex for t(11; 14)-positive RRMM.
- Darzalex (daratumumab) / J&J
INDIRECT TREATMENT COMPARISONS OF DARATUMUMAB-POMALIDOMIDE-DEXAMETHASONE (DPD) AND POMALIDOMIDE-BORTEZOMIB-DEXAMETHASONE (PVD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2453;
Our conclusion assumes that there were no significant imbalances in importantremaining prognostic or effect-modifying variables after adjusting for the selected covariates in the population-adjusted indirect comparisons. In the absence of a randomized controlled trial, these results provide valuableinsights with respect to the added benefit of DPd over PVd in RRMM.
- Ninlaro (ixazomib) / Takeda
IN-CLASS TRANSITION FROM PARENTERAL BORTEZOMIB (V) TO ORAL IXAZOMIB IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF US MM-6 OVERALL AND BY PATIENT (PT) SUBGROUPS OF INTEREST (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2452;
P4
The expecteddecrement in outcomes associated with older, frail, and RCT-ineligible pts was observed; however, these resultswere not statistically significant. Long-term triplet consolidation with IRd may provide an alternative approachto induction/maintenance for community-based NDMM pts who are not eligible for upfront transplantation,including those who are older, frail, and/or have comorbidities.
- dexamethasone / Generic mfg., lenalidomide / Generic mfg., carfilzomib / Generic mfg.
CARDIOVASCULAR TOXICITY AFTER CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE COMBINATION CHEMOTHERAPY IN THE REAL-WORLD ASIAN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2450;
Cardiovascular event after carfilzomib-basedregimen did not affect progression-free or overall survival in RRMM patients. The recognition and managementof underlying HTN has the utmost importance amongst the CV risk factors to mitigate CVAE in the AsianRRMM patients treated with KRd regimen.
- Darzalex (daratumumab) / J&J
REAL-WORLD CHARACTERISTICS AND OUTCOMES FOR LENALIDOMIDE-REFRACTORY PATIENTS WITH MULTIPLE MYELOMA RECEIVING DARATUMUMAB (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2444;
The recognition and managementof underlying HTN has the utmost importance amongst the CV risk factors to mitigate CVAE in the AsianRRMM patients treated with KRd regimen. To address the unmet need for additional triplet regimen options at2L for lenalidomide-refractory patients, the DREAMM-7 and DREAMM-8 trials are investigating the efficacy andsafety of belantamab mafodotin in combination with bortezomib
- Darzalex (daratumumab) / J&J
THE RISING UNMET NEED FOR MULTIPLE MYELOMA PATIENTS AFTER FIRST-LINE TREATMENT WITH DRD: AN EPIDEMIOLOGICAL ESTIMATE IN ITALY BETWEEN 2024-2028 () - May 15, 2024 - Abstract #EHA2024EHA_2428;
Background: In 2021, the combination treatment daratumumab plus lenalidomide and dexamethasone (DRd) wasreimbursed in Italy for the treatment of newly diagnosed Multiple Myeloma (MM) patients not eligible forautologous stem cell transplantation (NSCT), based on the remarkable clinical efficacy it demonstrated in theclinical trial MAIA. This study highlights the increasing unmet medical need developing in the 2L setting due to the large numberof patients relapsing after 1L therapy with DRd in Italy, for whom available treatment options are very limitedas the patients might not be eligible for DRd due to factors such as their age, disease severity, and thepresence of comorbidities.
- bortezomib / Generic mfg., dexamethasone / Generic mfg., thalidomide / Generic mfg.
THE SIDE-EFFECT BURDEN OF TREATMENTS IN MULTIPLE MYELOMA IN A REAL-WORLD POPULATION: EXPLORING THE ONGOING IMPACT OF SIDE-EFFECTS ON THE DAILY LIVES OF PATIENTS () - May 15, 2024 - Abstract #EHA2024EHA_2412;
Whilstperipheral neuropathy was highly prevalent and often experienced for more than a year post-treatment, it hada low impact on patients' daily lives, suggesting patients were self-managing this side-effect and/or beingcarefully monitored by their healthcare team, i. e. a dose reduction was made to counter this side-effect. A lackof energy, weakness, or fatigue had a considerable and ongoing impact on MM patients.
- Ninlaro (ixazomib) / Takeda, Cotellic (cobimetinib) / Exelixis, Roche
MEK1/2 INHIBITION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS INDUCES IRF1-MEDIATED INTERFERON/PD-L1 SIGNALING AXES IN THE BONE MARROW IMMUNE MICROENVIRONMENT (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2400;
P1/2
These data indicate that targeted kinase inhibition with cobimetinib and dexamethasone activates IRF1-mediated IRF1/IFNg and PD-L1 signaling axes in the tumor microenvironment of RRMM patients. These resultssupport further explorations of rational combinations of targeted and immune therapies for greater efficacy inthis disease.
- Darzalex (daratumumab) / J&J, iberdomide (CC-220) / BMS
IBERDOMIDE IS IMMUNE STIMULATORY AND INDUCES DEEP ANTI-MYELOMA ACTIVITY ACROSS DOSES IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH TNE NDMM FROM THE CC-220-MM-001 STUDY (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2363;
P1/2
Notably, data showedsignificant overlap across doses suggesting all 3 doses of IBER tested are biologically active in combination withDARA + DEX. These data support the use of IBER at doses of 1.
- Darzalex (daratumumab) / J&J
INFLAMMATORY BONE MARROW MICROENVIRONMENT IMPAIRS RESPONSES TO DARATUMUMAB AND LENALIDOMIDE IN MULTIPLE MYELOMA. A CORRELATIVE STUDY OF THE IFM2017-03 TRIAL. (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2362;
P3
Specifically, this adverse BME is linked to reduced CD16 expression in theseimmune cells of NR versus CR patients. Our findings shed light on the pivotal role the BME plays in influencingthe efficacy of drug mechanisms, highlighting the potential of targeting inflammatory signaling pathways as astrategy to enhance therapeutic responses.
- dexamethasone / Generic mfg.
THE ORPHAN NUCLEAR RECEPTOR NR5A2 REGULATES PHOSPHOLIPID REMODELING VIA MBOAT1 AND MBOAT2 TO PROMOTE PROLIFERATION AND DRUG RESISTANCE IN MULTIPLE MYELOMA CELLS (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2342;
The orphan nuclear receptor NR5A2 regulates phospholipid remodeling via MBOAT1 and MBOAT2, inhibitingferroptosis in HMCLs, promoting proliferation, and inducing resistance to dexamethasone in HMCLs. This studyprovides new insights into the pathogenesis of MM and offers novel therapeutic targets for MM treatment.
- Inqovi (decitabine/cedazuridine) / Otsuka
ES-3000, A WNT/ ? CATENIN/INFLAMMASOME PATHWAY INHIBITOR COMBINED WITH ORAL DECITABINE/CEDAZURIDINE(ASTX727) FOR PATIENTS WITH MYELODYSPLASIA (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2293;
The oral-oral combination of ES-3000 and ASTX727 is attractive given the mechanisms of action and potential synergies. Figure.
- Inqovi (decitabine/cedazuridine) / Otsuka
ASSESSMENT OF CLINICAL OUTCOMES OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) WHO WERE TREATED WITH ORAL DECITABINE/CEDAZURIDINE (DEC-C) USING THE INTERNATIONAL WORKING GROUP (IWG) 2023 CRITERIA (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2268;
P1/2, P3
As expected, transfusion dependency at baseline, TP53mutations, and higher-risk IPSS-M categories were associated with inferior survival. Additional analyses will bepresented.
- eltanexor (KPT-8602) / Karyopharm, Xpovio (selinexor) / Karyopharm
INHIBITION OF NUCLEAR EXPORT PROMOTES EXPANDED NK CELL AND ANTI-CD19 CAR NK CELL LYSIS OF MALIGNANT B CELLS VIA DISRUPTION OF NKG2A (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2067;
P1/2
Additionally,anti-CD19 CAR NK cell cytotoxicity was enhanced with selinexor. This effect occurs via downregulation of HLA-E and release of inhibitory NKG2A signaling.
- Epkinly (epcoritamab-bysp) / Genmab, AbbVie
EPCORITAMAB INDUCES DEEP RESPONSES IN RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): SAFETY AND POOLED EFFICACY DATA FROM EPCORE NHL?1 PIVOTAL AND CYCLE (C) 1 OPTIMIZATION (OPT) FL COHORTS (Hall Dali 2) - May 15, 2024 - Abstract #EHA2024EHA_2039;
P1/2
Safety was manageable in both cohorts, and CRS rate and severity were substantially reduced with C1 OPT, with few G2 and no G ? 3 events.
- Brukinsa (zanubrutinib) / BeiGene, Rituxan (rituximab) / Roche
FRONTLINE TREATMENT WITH ZANUBRUTINIB PLUS RITUXIMAB (ZR) FOLLOWED BY SHORT COURSE R-DHAOX IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2015;
P2
This strategy might reduce the toxicity of cytarabine-based chemotherapy without weakening thetherapeutic efficacy. Table 1.
- odronextamab (REGN1979) / Regeneron, Lunsumio (mosunetuzumab-axgb) / Roche, Biogen, Epkinly (epcoritamab-bysp) / Genmab, AbbVie
MATCHING-ADJUSTED INDIRECT COMPARISONS OF EPCORITAMAB VS MOSUNETUZUMAB OR ODRONEXTAMAB IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AFTER ?2 SYSTEMIC THERAPIES (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_1992;
P1/2, P2
Notwithstanding the limitations of the study,these findings underscore the benefits of epcoritamab in R/R FL. Table.
- Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
IBRUTINIB, LENALIDOMIDE AND RITUXIMAB IN RELAPSED MANTLE CELL LYMPHOMA - LONG TERM FOLLOW-UP OF THE NORDIC LYMPHOMA GROUP MCL6 PHILEMON TRIAL (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_1989;
The median PFSof 17. 4 months is longer than the median PFS of 12.
- Epkinly (epcoritamab-bysp) / Genmab, AbbVie
MODEL-BASED CYCLE (C) 1 OPTIMIZATION OF STEP-UP DOSE REGIMEN FOR EPCORITAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_1964;
P1/2
4 months is longer than the median PFS of 12. PK/PD and exposure
- Epkinly (epcoritamab-bysp) / Genmab, AbbVie
MINIMAL RESIDUAL DISEASE (MRD), PHARMACOKINETIC (PK), AND PHARMACODYNAMIC (PD) ASSESSMENT OF EPCORITAMAB 2- VS 3-STEP STEP-UP DOSING IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL) (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_1963;
P1/2
MRD-negativity rate and kinetics, PK, longitudinal peripheral B?cell depletion, and T-cell counts were similarbetween groups and consistent with comparable clinical efficacy reported for the C1 OPT and 2-step SUDregimens. In contrast, IL-6 levels were substantially reduced for C1 OPT vs the 2-step SUD regimen.
- Rituxan (rituximab) / Roche
REAL-LIFE TREATMENT PRACTICE AND CLINICAL OUTCOMES IN EGYPTIAN CLASSICAL HODGKIN LYMPHOMA PATIENTS: THE PROFILE STUDY () - May 15, 2024 - Abstract #EHA2024EHA_1941;
0%) ofpatients had received an ABVD regimen (doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, anddacarbazine), 1. 1% CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
- Adcetris (brentuximab vedotin) / Takeda, Pfizer
OUTCOMES OF TREATMENT FOR PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA AND THE ROLE OF PET-CT: A MONOCENTRIC STUDY. () - May 15, 2024 - Abstract #EHA2024EHA_1937;
Chemosensitivity remains the best predictor of response to peripheral stem cellautotransplantation, hence the importance of assessing response to treatment by PET. PET is an integral part ofthe management of Hodgkin's lymphoma, and should be performed for staging and response assessment toguide treatment.
- Adcetris (brentuximab vedotin) / Takeda, Pfizer
MOBILIZATION AND HARVEST OF STEM CELLS AFTER SALVAGE THERAPY WITH BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA () - May 15, 2024 - Abstract #EHA2024EHA_1921;
8 mg/kg, day 1), cisplatin (100 mg/m2, day 1),cytarabine (4 g/m2, day 2) and dexamethasone (40 mg, days 1-4). Our results would suggest BV does not adversely affect stem cell mobilization.
- Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen
OBINUTUZUMAB AS DEBULKING THERAPY FOR A SUCCESSFUL DELIVERED OF FIXED-DURATION VENETOCLAX () - May 15, 2024 - Abstract #EHA2024EHA_1754;
The patient underwent intravenous (IV) hydration, and daily urolithic therapy with rasburicase 7...Thereaction was treated with hydrocortisone 200 mg, chlorphenamine 10 mg, paracetamol 1000 mg, ondansetron8 mg, furosemide 20 mg and O2 supportive therapy... With proper support therapy, Obinutuzumab associated with Venetoclax represented a life-saving treatment, isable to normalize the blood counts and achieve a complete response also in CLL-patients with an extremelyhigh risk of TLS.
- TIME TO NEXT TREATMENT AFTER FIRST-LINE TREATMENT WITH TIME-LIMITED TARGETED AGENTS: A POOLED ANALYSIS OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITHIN CLINICAL TRIALS OF THE GCLLSG (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_1678;
9% of pts have receiveda 2L treatment. With the caveat of a pooled study population, longer time to first-line treatment and treatmentwith a triple combination (anti-CD20+BTKi+BCL2i-based) appear to correlate with longer TTNT following 1Ltreatment.
- Epkinly (epcoritamab-bysp) / Genmab, AbbVie
EPCORITAMAB + R-DHAX/C ELICITS DEEP, DURABLE RESPONSES IN TRANSPLANT-ELIGIBLE PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, INCLUDING HIGH-RISK DISEASE (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_1586;
P1/2
With the caveat of a pooled study population, longer time to first-line treatment and treatmentwith a triple combination (anti-CD20+BTKi+BCL2i-based) appear to correlate with longer TTNT following 1Ltreatment. Aims: To report longer follow-up on safety and efficacy from the EPCORE
- Epkinly (epcoritamab-bysp) / Genmab, AbbVie
EXTENDED FOLLOW-UP BEYOND 2.5 YEARS SHOWS LONG-TERM EFFICACY IN COMPLETE RESPONDERS FOLLOWING EPCORITAMAB MONOTHERAPY IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_1584;
P1/2
No new safety signals were reported . Simple measures of prophylactic dexamethasone and hydration in C1 decreased rates and severity of CRS and did not appear to impact efficacy.
- Tecartus (brexucabtagene autoleucel) / Gilead, Yescarta (axicabtagene ciloleucel) / Gilead
REAL LIFE EXPERIENCE FROM A SINGLE UNIT IN GREECE: EXCELLENT OUTCOME FOR MANTLE CELL LYMPHOMA (MCL) COMPARED TO DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) WITH CAR T CELL THERAPY () - May 15, 2024 - Abstract #EHA2024EHA_1571;
DLBCL 3rd line patients benefit from axi-cel in real life with a significantchance of cure. However, our initial experience in DLBCL 2nd line has been discouraging.
- Muphoran (fotemustine) / Servier, Rituxan (rituximab) / Roche
UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION CAN CURE A HIGH PERCENTAGE OF HIGH-INTERMEDIATE/HIGH-RISK AGGRESSIVE LYMPHOMA: RESULTS OF A MONOCENTRIC RETROSPECTIVE SERIES () - May 15, 2024 - Abstract #EHA2024EHA_1569;
Upfront ASCT consolidation is still an effective and safe strategy which can cure more than 80% of high-riskaggressive lymphoma patients with a single line of treatment. Pre-transplant PET could help as a predictivetool, but more specific biomarkers, such as ct-DNA evaluation, might allow to better tailor treatment in thenear future.
- Tevimbra (tislelizumab-jsgr) / BeiGene, Xpovio (selinexor) / Karyopharm
SELINEXOR COMBINED WITH TISLELIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY EXTRANODAL NK/T-CELL LYMPHOMA (R/R ENKTL): RESULTS OF DOSE ESCALATION OF COHORT C FROM PHASE I/II STUDY TOUCH () - May 15, 2024 - Abstract #EHA2024EHA_1545;
P1/2
Selinexor in combination of tislelizumab showed tolerable safety profile across 2 doselevels and promising efficacy results in R/R ENKTL. Expansion stage of Cohort C is ongoing.
- lenalidomide / Generic mfg.
R2-GDP WITH LENALIDOMIDE MAINTENANCE FOR TRANSPLANT-INELIGIBLE RELAPSE REFRACTORY DLBCL UNDER CLINICAL TRIAL AND REAL-WORLD SETTINGS () - May 15, 2024 - Abstract #EHA2024EHA_1515;
R2-GDP and lenalidomide maintenance is a feasible treatment option for relapse DLBCL but not primaryrefractory in clinical trial and real-world. It could be a useful regime to be used in resource-constraint setting,with observation of long-term disease control shown here.
- Actemra IV (tocilizumab) / Roche, JW Pharma, Tecartus (brexucabtagene autoleucel) / Gilead, Yescarta (axicabtagene ciloleucel) / Gilead
REAL WORLD DATA OF ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR ADULT PATIENTS WITH REFRACTORY/RELAPSED HIGH GRADE B CELL LYMPHOMA AND MANTLE CELL LYMPHOMA IN ONE CENTRE IN SOUTHERN GREECE. () - May 15, 2024 - Abstract #EHA2024EHA_1477;
The toxicity landscape of CAR-T cell therapies is becoming clearer by the day, as more real-world data arereported. The toxicities are manageable if recognised and treated early.